Proteomics-based Anticancer Drug Discovery and Development

被引:10
|
作者
Jain, K. K. [1 ]
机构
[1] Jain PharmaBiotech, CH-4057 Basel, Switzerland
关键词
Cancer; proteomics; drug discovery; drug targets; target validation; anticancer drugs;
D O I
10.1177/153303460200100403
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Proteins are important targets for drug discovery and this applied to cancer as well because there is a defect in the protein machinery of the cell in malignancy. Proteomic technologies are now being integrated with genomic approaches for cancer drug discovery and target validation. Among the large number of proteomic technologies available for this purpose, the most important ones are 3-D protein structure determination, protein microarrays, laser capture microdissection and study of protein-protein and protein-drug interactions. Cancer biomarkers and several cell pathways are important drug targets. Several companies are involved in using proteomic technologies for drug discovery. Finally, proteomic approaches will play an important role in the discovery and development of personalized medicines.
引用
收藏
页码:231 / 236
页数:6
相关论文
共 50 条
  • [31] Chemical proteomics for drug discovery based on compound-immobilized affinity chromatography
    Katayama, Hiroyuki
    Oda, Yoshiya
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 855 (01): : 21 - 27
  • [32] Proteomics for drug target discovery
    Gottfries, J
    Sjögren, M
    Holmberg, B
    Rosengren, L
    Davidsson, P
    Blennow, K
    CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS, 2004, 73 (01) : 47 - 53
  • [33] Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma
    Alaiya, Ayodele A.
    Al-Mohanna, Mai
    Aslam, Muhammad
    Shinwari, Zakia
    Al-Mansouri, Layla
    Al-Rodayan, Maha
    Al-Eid, Maha
    Ahmad, Irfan
    Hanash, Kamal
    Tulbah, Asma
    Bin Mahfooz, Ali
    Adra, Chaker
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 38 (04) : 1047 - 1057
  • [34] Next-Generation Proteomics-Based Discovery, Verification, and Validation of Urine Biomarkers for Bladder Cancer Diagnosis
    Suh, Jungyo
    Han, Dohyun
    Ku, Ja Hyeon
    Kim, Hyeon Hoe
    Kwak, Cheol
    Jeong, Chang Wook
    CANCER RESEARCH AND TREATMENT, 2022, 54 (03): : 882 - 893
  • [35] Plant Metabolomics: The Future of Anticancer Drug Discovery
    Dabbousy, Ranin
    Rima, Mohamad
    Roufayel, Rabih
    Rahal, Mohamad
    Legros, Christian
    Sabatier, Jean-Marc
    Fajloun, Ziad
    PHARMACEUTICALS, 2024, 17 (10)
  • [36] Anticancer drug discovery using chemical genomics
    Sehgal, A
    CURRENT MEDICINAL CHEMISTRY, 2003, 10 (09) : 749 - 755
  • [37] Heterocyclic Compounds: Importance in Anticancer Drug Discovery
    Kumar, Naresh
    Goel, Nidhi
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2022, 22 (19) : 3196 - 3207
  • [38] Anticancer drug discovery targeting DNA hypermethylation
    Yu, Niefang
    Wang, Mingrong
    CURRENT MEDICINAL CHEMISTRY, 2008, 15 (14) : 1350 - 1375
  • [39] Triazole-fused pyrimidines in target-based anticancer drug discovery
    Dai, Xing-Jie
    Xue, Lei-Peng
    Ji, Shi-Kun
    Zhou, Ying
    Gao, Ya
    Zheng, Yi-Chao
    Liu, Hui-Min
    Liu, Hong-Min
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 249
  • [40] Proteomics-Based Biomarkers in Chronic Obstructive Pulmonary Disease
    Chen, Hong
    Wang, Diane
    Bai, Chunxue
    Wang, Xiangdong
    JOURNAL OF PROTEOME RESEARCH, 2010, 9 (06) : 2798 - 2808